WHO announces landmark changes in MDR-TB treatment regimens

August 18, 2018
Geneva, August 18, 2018:

Major improvement in treatment outcomes and quality of life of patients with multidrug-resistant tuberculosis (MDR-TB) are expected, following key changes in MDR-TB treatment announced by WHO today.

The first important change is a new priority ranking of the available medicines for MDR-TB treatment, based on a careful balance between expected benefits and harms. Treatment success for MDR-TB is currently low in many countries. This could be increased by improving access to the highest-ranked medicines for all patients with MDR-TB.

The second important change is a fully oral regimen as one of the preferred options for MDR-TB treatment, with injectable agents proposed to be replaced by more potent alternatives such as bedaquiline (the first-ever medicine to be developed specifically for the treatment of MDR-TB). Injectable agents cause pain and distress to patients, with many experiencing serious adverse effects that often lead to treatment being interrupted.

“The treatment landscape for patients with MDR-TB will be dramatically transformed for the better with the announcement today,” said Dr Soumya Swaminathan, WHO Deputy Director-General for Programmes. “Building on the available new data, and with the involvement of a large number of stakeholders, WHO has moved forward in rapidly reviewing the evidence and communicating the key changes needed to improve the chances of survival of MDRTB patients worldwide. Political momentum now needs to urgently accelerate, if the global crisis of MDR-TB is to be contained.”

The WHO rapid communication aims to encourage and prepare countries to implement the upcoming new consolidated, updated and more detailed WHO policy guidelines on MDR-TB treatment which will be released later this year. WHO is also establishing a multi-stakeholder Task Force to coordinate support to national TB programmes in their rapid transition to the key changes envisaged.

An evidence-driven process

The announcement follows an in-depth assessment of the latest evidence on the efficacy and safety of medicines available to treat MDR-TB by an independent panel of experts convened by WHO. The outcomes of the meeting, held 16-20 July, also have major and immediate implications for countries, donors and technical partners as clinical care, national diagnostic and treatment policies, medicine and diagnostic procurement strategies, and training plans will require rapid review and adaptation.

The meeting was the culmination of an extensive process initiated by WHO in 2017. Following WHO’s public call for data, anonymized individual patient records from clinical trials, observational studies and national TB programmes were incorporated into a global database hosted by McGill University, Canada under contract with WHO. International standards for data analyses by the McGill group ensured high confidence in the findings and enabled WHO to rapidly communicate the key changes.

“Evidence-based interventions are essential for optimal clinical care of patients and effective public health service delivery,” said Professor Holger Schünemann, Director of Cochrane Canada and member of the International GRADE Working Group, who chaired the expert panel meeting. “WHO is a leader in ensuring that its policies and guidelines meet the highest scientific standards, which should generate full trust by its member states and other stakeholders.”

MDR-TB – a global public health crisis

TB is among the oldest diseases known to mankind, yet remains one of the top 10 causes of death worldwide today, as well as the leading global infectious disease killer. About 600,000 new cases of MDR-TB (or other rifampicin-resistant TB) emerge each year and about 240,000 people die of these forms of TB each year according to WHO estimates.

MDR-TB is a major driver of antimicrobial resistance worldwide and threatens hard-earned gains made in the global TB response over the past twenty years. Diagnosis and treatment of MDR-TB remain a major challenge, with only one in four affected people currently being detected and even fewer being treated successfully.

Moving forward

“We would like to thank countries, technical partners, donors, civil society and other key TB stakeholders for their contribution that has culminated in these positive changes for MDR-TB patients,” said Dr Tereza Kasaeva, Director of WHO’s Global TB Programme. “We now ask for their urgent support to national TB programmes in their transition to new MDR-TB treatment regimens.”

Accelerated efforts to address the MDR-TB crisis will contribute to accelerating action to end the global TB epidemic. Heads of State, Government and other global leaders are poised to gather at the first-ever United Nations High-level Meeting on TB in New York on 26 September 2018.

Stay informed with the latest news from HealthySoch. Sign up today for exclusive insights and updates!

We promise we never spam!

Leave a Reply

Your email address will not be published.

Health Tips

Dr. T S Kler Padma Bhushan Awardee
MD, DM, MRCP, FRCP(U.K), FACC, D.Sc
Chairman – Fortis Heart Institute Gurugram

Precautions to avoid Corona Virus:

  1. Stay home as far as possible.
  2. Wash hands with soap and water frequently.
  3. Keep distance from people even your home members.
  4. Keep atleast 1-2 metres away from anybody coughing.
  5. Don’t touch your face, nose and mouth.

 

Dr. K.K Says

Archives

MonTueWedThuFriSatSun
    123
45678910
18192021222324
25262728293031
       
   1234
567891011
12131415161718
26272829   
       
891011121314
293031    
       
    123
45678910
11121314151617
25262728293031
       
  12345
6789101112
13141516171819
27282930   
       
      1
2345678
9101112131415
16171819202122
3031     
     12
17181920212223
24252627282930
31      
   1234
567891011
12131415161718
2627282930  
       
1234567
891011121314
22232425262728
293031    
       
     12
3456789
17181920212223
24252627282930
       
  12345
6789101112
       
  12345
13141516171819
2728     
       
      1
9101112131415
3031     
   1234
567891011
       
282930    
       
    123
45678910
       
  12345
27282930   
       
      1
3031     
    123
11121314151617
       
28      
       
2930     
       
    123
       
       
       
      1
9101112131415
3031     
     12
3456789
10111213141516
17181920212223
242526272829 
       
  12345
13141516171819
2728293031  
       
      1
23242526272829
3031     
    123
       
    123
25262728   
       
78910111213
28293031   
       
293031    
       
14151617181920
28293031   
       
   1234
567891011
       
   1234
567891011
262728    
       
891011121314
293031    
       
    123
18192021222324
25262728293031
       
  12345
27282930   
       
      1
2345678
16171819202122
3031     
    123
45678910
18192021222324
       
28293031   
       
     12
31      
   1234
       
  12345
6789101112
       
HealthySoch

Don't Miss

Madhavbaug puts Scientific Evidence-based Ayurveda on Global Map

“4th International Ayurveda Cardiology Symposium was organised in Azerbaijan by

Eye-Q Reaches Landmark with Treatment of 75 Lakh Patients Since Inception

In the year 2023 alone, Eye-Q serviced a total of